Assembly Biosciences (FRA:V7B) Ending Cash Position: €28.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V7B Assembly Biosciences Inc FRA:V7B
34 GF Score
Price €27.05
GF Value €17.56
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Ending Cash Position?

Assembly Biosciences FRA:V7B +7.13% 34 Ending Cash Position is €28.02 Mil as of Jun. 2026. GuruFocus rates FRA:V7B with a GF Score™ of 34/100 and a GF Value™ of €17.56 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Assembly Biosciences's Ending Cash Position for the quarter that ended in Jun. 2026 was €28.02 Mil.

Assembly Biosciences's quarterly Ending Cash Position declined from Dec. 2025 (€49.92 Mil) to Mar. 2026 (€26.92 Mil) but then increased from Mar. 2026 (€26.92 Mil) to Jun. 2026 (€28.02 Mil).

Assembly Biosciences's annual Ending Cash Position increased from Dec. 2023 (€18.19 Mil) to Dec. 2024 (€36.62 Mil) and increased from Dec. 2024 (€36.62 Mil) to Dec. 2025 (€49.92 Mil).

Assembly Biosciences Ending Cash Position Related Terms

Assembly Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Ending Cash Position Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.38 49.48 18.19 36.62 49.92

Assembly Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.81 19.20 49.92 26.92 28.02
FRA:V7B
34GF Score
Assembly Biosciences Inc FRA:V7B
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Assembly Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=32.745+17.171
=49.92

Assembly Biosciences's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=27.012+1.012
=28.02

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €28.02 Mil mean?
Assembly Biosciences (FRA:V7B) has a Ending Cash Position of €28.02 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Ending Cash Position too high?
Assembly Biosciences' current Ending Cash Position is €28.02 Mil. Overall, Assembly Biosciences has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Ending Cash Position compare to ZURA and ARVN?
Assembly Biosciences' Ending Cash Position of €28.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Ending Cash Position is €28.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Assembly Biosciences (FRA:V7B) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.56, compared to a current price of €27.05 — trading 54% above its estimated fair value. The current Ending Cash Position is €28.02 Mil. Assembly Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Assembly Biosciences (FRA:V7B), the current Ending Cash Position is €28.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Assembly Biosciences (FRA:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €27.05 is trading 54% above its estimated GF Value™ of €17.56. GuruFocus considers Assembly Biosciences to be Significantly Overvalued.

Key valuation signals for FRA:V7B:

  • Ending Cash Position: €28.02 Mil
  • GF Value™: €17.56 vs. price of €27.05 (54% above fair value)
  • GF Score™: 34/100 with 3 warning signs

No single metric tells the full story. See the FRA:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Assembly Biosciences Business Description

Other Exchanges ASMB:USAV7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
34GF Score

Get the complete analysis for FRA:V7B

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.05
Price
€17.56
GF Value